David A. Siegel Arvinas, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARVN
# of Institutions
234Shares Held
64.9MCall Options Held
119KPut Options Held
94.2K-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$167 Million7.92% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.3MShares$157 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.49MShares$137 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.37MShares$109 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY3.3MShares$82 Million2.18% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $1.32B
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...